The medicines make up a regimen that is being studied in multiple tumor types. Agenus could seek an approval in colorectal cancer next year. By zeroing in on botensilimab and balstilimab we expect to expedite regulatory approval and availability for healthcare providers and patients in need said Chairman and CEO Garo reflects our commitment to the success of these programs while optimizing shareholder value The company had 175 million in cash at the end of the second quarter enough to fund operations for about a year